A general role of AR in mediating inflammation and cytokine generation is consistent with our observations showing that inhibition of AR prevents PKC and NF-κB activation by a variety of stimuli, such as TNF-α, FGF, PDGF, angiotensin-II, and high glucose
25 43 44 and hyperglycemia-induced MAPK
45 and JAK2.
46 These findings suggest that AR could be an obligatory mediator of stress response including the activation of NF-κB and other PKC-sensitive transcription factors. Activation of NF-κB requires association of IKK (Inhibitor of kappaB kinase)-α, IKKβ, and IKKγ.
47 In LPS signaling, the IKKα/β complex is assembled through a TAK1-dependent pathway that also activates JNK and p38.
48 The observation that phosphorylation of both the JNK and p38 kinases in the HLECs was severely attenuated by AR inhibition
(Figs. 3C 8B)further suggests that the signals preceding TAK1 activation are prevented by ARIs and that the inhibition of AR does not directly interfere with the NF-κB and its downstream effectors. LPS-triggered signaling events further upstream to IKK activation are mediated by the activation of PKC, because macrophage PKC activity is increased by LPS stimulation, and PKC inhibitors prevent LPS-induced NF-κB activation and the release of cytokines.
49 50 In agreement with a central role of PKC, we found a marked PKC activation with LPS
(Fig. 8A) . AR inhibition or ablation prevented LPS-induced activation of PKC, supporting our previous observation that inhibition of AR prevents PKC activation and thus modulates the activity of NF-κB. Although the mechanisms by which AR facilitates PKC activation remains unclear, we propose that inhibition of AR prevents the events that could lead to the activation of PLC isozymes, which are activated by LPS, as observed in high-glucose–treated vascular smooth muscle cells (VSMCs).
43 Recently, we have reported that ARIs prevent phosphatidylinositol-specific phospholipase C (PI-PLC)–dependent synthesis of diacylglycerol in high-glucose–stimulated VSMCs.
43 A similar mechanism could account for the AR mediation of LPS-induced PKC and NF-κB activation in HLECs. Alternatively, AR inhibition could affect signaling due to products of lipid peroxidation or their glutathione conjugates.
51 Recent studies have shown that the oxidized phospholipids such as 1-palmitoyl, 2-oxovaleryl phosphocholine (POVPC), which is also a substrate of AR,
52 inhibit NF-κB activation and increase mortality in mice injected with lethal doses of LPS.
53 This indicates that the inhibition of AR could prevent activation of NF-κB by allowing oxidized phospholipids to accumulate in the cells.